ZEN003694 (NCT05071937)

Name: ZEN003694 trial for Ovarian Cancer (NCT05071937)
Uploaded: 2026-10-31T23:54:24.369Z
Duration: 1 min 29 s
Description: ZEN003694 trial for Ovarian Cancer (NCT05071937). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT05071937.

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer: a one-minute explainerNCT050719371 min

ZEN003694 trial for Ovarian Cancer (NCT05071937). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult women with recurrent ovarian, fallopian-tube, or primary peritoneal carcinoma after prior PARP-inhibitor treatment. BRCA status must be known; both platinum-sensitive and platinum-resistant disease qualify. Ovarian carcinosarcoma is excluded.

The idea: ZEN003694 blocks BET proteins that regulate growth-related genes; talazoparib blocks PARP-mediated DNA repair. Patients take both orally each day in four-week cycles, with a safety lead-in. Researchers measure tumor response. Prior BET-inhibitor treatment excludes participation.

This phase 2 study plans 33 patients. Alexander Olawaiye leads at UPMC, Pittsburgh, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.